Royal Bank of Canada’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-8,310
| Closed | -$564K | – | 7374 |
|
|
2019
Q3 | $564K | Sell |
8,310
-1,762
| -17% | -$121K | ﹤0.01% | 3764 |
|
|
2019
Q2 | $585K | Buy |
10,072
+1,466
| +17% | +$86.8K | ﹤0.01% | 3745 |
|
|
2019
Q1 | $603K | Buy |
8,606
+7,999
| +1,318% | +$593K | ﹤0.01% | 3607 |
|
|
2018
Q4 | $39K | Sell |
607
-382
| -39% | -$26.8K | ﹤0.01% | 5237 |
|
|
2018
Q3 | $69K | Buy |
989
+220
| +29% | +$12.9K | ﹤0.01% | 5072 |
|
|
2018
Q2 | $39K | Buy |
769
+608
| +378% | +$24.1K | ﹤0.01% | 5267 |
|
|
2018
Q1 | $5K | Sell |
161
-93
| -37% | -$3.09K | ﹤0.01% | 5960 |
|
|
2017
Q4 | $8K | Sell |
254
-1,698
| -87% | -$54.1K | ﹤0.01% | 5957 |
|
|
2017
Q3 | $63K | Buy |
1,952
+1,763
| +933% | +$55.6K | ﹤0.01% | 5290 |
|
|
2017
Q2 | $6K | Sell |
189
-900
| -83% | -$28.5K | ﹤0.01% | 6009 |
|
|
2017
Q1 | $33K | Sell |
1,089
-266
| -20% | -$7.87K | ﹤0.01% | 5378 |
|
|
2016
Q4 | $40K | Buy |
1,355
+1,254
| +1,242% | +$38.2K | ﹤0.01% | 5395 |
|
|
2016
Q3 | $3K | Sell |
101
-3,365
| -97% | -$93.8K | ﹤0.01% | 6128 |
|
|
2016
Q2 | $90K | Sell |
3,466
-5,037
| -59% | -$134K | ﹤0.01% | 4836 |
|
|
2016
Q1 | $210K | Buy |
8,503
+8,375
| +6,543% | +$230K | ﹤0.01% | 4339 |
|
|
2015
Q4 | $5K | Sell |
128
-14,900
| -99% | -$399K | ﹤0.01% | 6183 |
|
|
2015
Q3 | $317K | Buy |
15,028
+4,494
| +43% | +$116K | ﹤0.01% | 3940 |
|
|
2015
Q2 | $293K | Buy |
10,534
+10,209
| +3,141% | +$288K | ﹤0.01% | 4069 |
|
|
2015
Q1 | $10K | Sell |
325
-19,945
| -98% | -$634K | ﹤0.01% | 5581 |
|
|
2014
Q4 | $648K | Buy |
20,270
+17,540
| +642% | +$571K | ﹤0.01% | 3311 |
|
|
2014
Q3 | $77K | Sell |
2,730
-6,975
| -72% | -$194K | ﹤0.01% | 4748 |
|
|
2014
Q2 | $266K | Buy |
9,705
+8,705
| +871% | +$232K | ﹤0.01% | 3957 |
|
|
2014
Q1 | $26K | Sell |
1,000
-21,533
| -96% | -$618K | ﹤0.01% | 5106 |
|
|
2013
Q4 | $660K | Buy |
22,533
+6,835
| +44% | +$217K | ﹤0.01% | 3202 |
|
|
2013
Q3 | $480K | Buy |
15,698
+4,130
| +36% | +$138K | ﹤0.01% | 3402 |
|
|
2013
Q2 | $366K | Buy |
+11,568
| New | +$380K | ﹤0.01% | 3416 |
|
Royal Bank of Canada's GHDX Position: Q4 2019 in Review
Royal Bank of Canada sold out of Genomic Health, Inc. (GHDX) in Q4 2019, closing a stake of 8,310 shares — an estimated $564K sold.
Royal Bank of Canada first reported a position in GHDX in Q2 2013 and held it in 26 quarters. The position peaked at $660K in Q4 2013. 0 funds tracked by Wall St. Rank hold GHDX as of Q4 2019.
- Royal Bank of Canada reported no remaining Genomic Health, Inc. position as of Q4 2019 after selling out during the quarter.
- Royal Bank of Canada sold 8,310 Genomic Health, Inc. shares in Q4 2019, an estimated $564K.
- Royal Bank of Canada first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 26 quarters.
- Royal Bank of Canada's Genomic Health, Inc. position peaked at $660K in Q4 2013.
- 0 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q4 2019.
Based on Royal Bank of Canada's 13F filing for Q4 2019, filed 14 Feb 2020.